Aktis Oncology, Inc. - Common stock (AKTS) analyst actions
Rating and price-target actions on AKTS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AKTS overview →
2 measured AKTS analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3 | Press release | +0.72% | -4.58% | |
| Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Press release | +0.00% | +2.26% |
Keep exploring
More AKTS: earnings → · SEC filings → · AKTS overview →
Other Technology names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Frequency Electronics, Inc. (FEIM) | 132 | -0.06% | 45% |
| THIN FILM ELECTRONICS ASA AME (TFECY) | 132 | 0.00% | 13% |
| GREENE CONCEPTS INC NEW (INKW) | 129 | 0.00% | 36% |
| LGL Group, Inc. (The) (LGL) | 129 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.